维拉帕米与其他钙通道阻滞剂相比的2型糖尿病发生率
中位随访1.6年,维拉帕米组2型糖尿病发生率为8.8/1000人年,其他钙通道阻滞剂组为11.4/1000人年,完全校正后发生率比为0.77(95%CI 0.63-0.94),6年2型糖尿病概率较低。结论认为维拉帕米使用与其他钙通道阻滞剂相比与较低的2型糖尿病发生率相关。
要点
- 维拉帕米组2型糖尿病发生率为8.8/1000人年,其他钙通道阻滞剂组为11.4/1000人年。
- 完全校正后发生率比为0.77(95%CI 0.63-0.94),支持维拉帕米。
- 6年2型糖尿病概率维拉帕米组4.2%(95%CI 3.3-5.3),其他钙通道阻滞剂组5.4%(95%CI 4.7-6.3)。
核心结论
- 与其他钙通道阻滞剂相比,维拉帕米使用与较低的2型糖尿病发生率相关。
研究设计与样本
- 基于澳大利亚全国补贴医疗数据库随机抽样的基于人群队列研究。
- 队列中维拉帕米使用者4,485人(5.0%),其他钙通道阻滞剂使用者85,541人(多为二氢吡啶类)。
- 采用多状态泊松回归模型,经多变量倾向评分校正后分析钙通道阻滞剂亚类与2型糖尿病发生率及死亡(竞争事件)的关联。
主要发现
- 中位随访1.6年,维拉帕米组101人发生2型糖尿病(8.8/1000人年),其他钙通道阻滞剂组2,622人发生(11.4/1000人年)。
- 完全校正后发生率比为0.77(95%CI 0.63-0.94),支持维拉帕米。
- 典型临床特征下6年2型糖尿病概率为4.2%(95%CI 3.3-5.3)对5.4%(95%CI 4.7-6.3),绝对风险差1.3%(95%CI -0.1-2.4)。
- 结果在多项敏感性分析中稳健。
临床怎么用
- 对于需要钙通道阻滞剂且存在2型糖尿病风险的患者,维拉帕米可能与较低的2型糖尿病发生率相关,可作为个体化选药参考。
局限性
- 随访中位时间仅1.6年,长期关联未充分评估。
- 为观察性队列研究,尽管经倾向评分校正,仍不能排除残余混杂。
- 维拉帕米组样本量相对较小(4,485人),事件数有限。
- 结局基于补贴数据库的治疗记录或登记,可能存在漏诊或分类偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Evidence that the calcium channel blocker (CCB) verapamil slows type 1 diabetes progression suggests possible preventive benefits among people at risk of developing type 2 diabetes. We compared type 2 diabetes incidence between users of verapamil versus other CCBs in a population-based cohort. RESEARCH DESIGN AND METHODS: From a random sample of Australians in national subsidized health care databases, we identified 90,026 individuals who initiated treatment with a CCB (at least two supplies) between July 2003 and December 2014. Incident diabetes was captured by subsequent receipt of glucose-lowering treatment or registration with the National Diabetes Services Scheme. Individuals were followed from first CCB supply until discontinuation, diabetes onset, death, or end of 2014. Multistate Poisson regression models characterized associations of CCB subclass with type 2 diabetes incidence and death (the competing event), after multivariable propensity score adjustment. RESULTS: The cohort comprised 4,485 verapamil users (5.0%) and 85,541 treated with other CCBs (mostly dihydropyridines). During a median 1.6-year follow-up, 101 individuals treated with verapamil developed type 2 diabetes (8.8 per 1,000 person-years) compared with 2,622 people treated with other CCBs (11.4 per 1,000 person-years). This translated to an incidence rate ratio of 0.77 (95% CI 0.63-0.94) in favor of verapamil (fully adjusted) and a lower probability of type 2 diabetes at 6 years (4.2% [95% CI 3.3-5.3] vs. 5.4% [4.7-6.3] for a typical clinical profile; absolute risk difference 1.3% [95% CI -0.1-2.4]). Results were robust across multiple sensitivity analyses. CONCLUSIONS: Verapamil use is associated with a lower incidence of type 2 diabetes compared with other CCBs.
引用
- Sacre JW, Wentworth JM, Magliano DJ, et al. Incidence of Type 2 Diabetes With Verapamil Compared With Other Calcium Channel Blockers. Diabetes Care. 2025. PMID: 41166560. doi:10.2337/dc25-1440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。